|
1
|
Lee JS, Fetsch JF, Wasdhal DA, Lee BP,
Pritchard DJ and Nascimento AG: A review of 40 patients with
extraskeletal osteosarcoma. Cancer. 76:2253–2259. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Young G, Toretsky JA, Campbell AB and
Eskenazi AE: Recognition of common childhood malignancies. Am Fam
Physician. 61:2144–2154. 2000.PubMed/NCBI
|
|
4
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21(Suppl 7): vii320–325. 2010.PubMed/NCBI
|
|
5
|
Fung KL, Pan J, Ohnuma S, Lund PE, Pixley
JN, Kimchi-Sarfaty C, Ambudkar SV and Gottesman MM: MDR1 synonymous
polymorphisms alter transporter specificity and protein stability
in a stable epithelial monolayer. Cancer Res. 74:598–608. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gromnicova R, Romero I and Male D:
Transcriptional control of the multi-drug transporter ABCB1 by
transcription factor Sp3 in different human tissues. PLoS One.
7:e481892012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson WW: P-glycoprotein-mediated efflux
as a major factor in the variance of absorption and distribution of
drugs: Modulation of chemotherapy resistance. Methods Find Exp Clin
Pharmacol. 24:501–514. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorokin A: Cyclooxygenase-2: Potential
role in regulation of drug efflux and multidrug resistance
phenotype. Curr Pharm Des. 10:647–657. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patel VA, Dunn MJ and Sorokin A:
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol
Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: An update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165.
2003.PubMed/NCBI
|
|
11
|
Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao
J, Li Z, Wu G and Guo Q: Oroxylin A reverses
P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by
G2/M arrest. Toxicol Lett. 219:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ronaldson PT, Ashraf T and Bendayan R:
Regulation of multidrug resistance protein 1 by tumor necrosis
factor alpha in cultured glial cells: Involvement of nuclear
factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol
Pharmacol. 77:644–659. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barancík M, Bohácová V, Kvackajová J,
Hudecová S, Krizanová O and Breier A: SB203580, a specific
inhibitor of p38-MAPK pathway, is a new reversal agent of
P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci.
14:29–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JY, Tanabe S, Shimohira H, Kobayashi
Y, Oomachi T, Azuma S, Ogihara K and Inokuma H: Expression of
cyclooxygenase-2, P-glycoprotein and multi-drug
resistance-associated protein in canine transitional cell
carcinoma. Res Vet Sci. 83:210–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi BH, Kim CG, Lim Y, Shin SY and Lee
YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by
inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett.
259:111–118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bentires-Alj M, Barbu V, Fillet M, Chariot
A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NF-kappaB
transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Zhao Y, Wang C, Xiao X, Zhou X and
Xu G: Inhibition of p38 MAPK diminishes doxorubicin-induced drug
resistance associated with P-glycoprotein in human leukemia K562
cells. Med Sci Monit. 18:BR383–BR388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Torres P, Poveda A, Jimenez-Barbero J,
Ballesteros A and Plou FJ: Regioselective lipase-catalyzed
synthesis of 3-o-acyl derivatives of resveratrol and study of their
antioxidant properties. J Agric Food Chem. 58:807–813. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Quan F, Pan C, Ma Q, Zhang S and Yan L:
Reversal effect of resveratrol on multidrug resistance in KBv200
cell line. Biomed Pharmacother. 62:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huo X, Liu Q, Wang C, Meng Q, Sun H, Peng
J, Ma X and Liu K: Enhancement effect of P-gp inhibitors on the
intestinal absorption and antiproliferative activity of bestatin.
Eur J Pharm Sci. 50:420–428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du J, Pan Y, Shi Y, Guo C, Jin X, Sun L,
Liu N, Qiao T and Fan D: Overexpression and significance of prion
protein in gastric cancer and multidrug-resistant gastric carcinoma
cell line SGC7901/ADR. Int J Cancer. 113:213–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim K, Kim KH, Kim HY, Cho HK, Sakamoto N
and Cheong J: Curcumin inhibits hepatitis C virus replication via
suppressing the Akt-SREBP-1 pathway. FEBS Lett. 584:707–712. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bae CH, Kim JW, Ye SB, Song SY, Kim YW,
Park SY and Kim YD: AMPK induces MUC5B expression via p38 MAPK in
NCI-H292 airway epithelial cells. Biochem Biophys Res Commun.
409:669–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sinha K, Chaudhary G and Gupta YK:
Protective effect of resveratrol against oxidative stress in middle
cerebral artery occlusion model of stroke in rats. Life Sci.
71:655–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gupta YK, Briyal S and Chaudhary G:
Protective effect of trans-resveratrol against kainic acid-induced
seizures and oxidative stress in rats. Pharmacol Biochem Behav.
71:245–249. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bishayee A, Barnes KF, Bhatia D, Darvesh
AS and Carroll RT: Resveratrol suppresses oxidative stress and
inflammatory response in diethylnitrosamine-initiated rat
hepatocarcinogenesis. Cancer Prev Res (Phila). 3:753–763. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z, Wang C, Wei L, Wang J, Fan Y,
Wang L, Wang Y and Chen T: Resveratrol inhibits EMMPRIN expression
via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem
Biophys Res Commun. 374:517–521. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
El-Mowafy AM and White RE: Resveratrol
inhibits MAPK activity and nuclear translocation in coronary artery
smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS
Lett. 451:63–67. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun C, Hu Y, Liu X, Wu T, Wang Y, He W and
Wei W: Resveratrol downregulates the constitutional activation of
nuclear factor-kappaB in multiple myeloma cells, leading to
suppression of proliferation and invasion, arrest of cell cycle,
and induction of apoptosis. Cancer Genet Cytogenet. 165:9–19. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu H, Pan C, Zhao S, Wang Z, Zhang H and
Wu W: Resveratrol inhibits tumor necrosis factor-alpha-mediated
matrix metalloproteinase-9 expression and invasion of human
hepatocellular carcinoma cells. Biomed Pharmacother. 62:366–372.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berghe W Vanden, Plaisance S, Boone E, De
Bosscher K, Schmitz ML, Fiers W and Haegeman G: p38 and
extracellular signal-regulated kinase mitogen-activated protein
kinase pathways are required for nuclear factor-kappaB p65
transactivation mediated by tumor necrosis factor. J Biol Chem.
273:3285–3290. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mulakayala C, Babajan B, Madhusudana P,
Anuradha CM, Rao RM, Nune RP, Manna SK, Mulakayala N and Kumar CS:
Synthesis and evaluation of resveratrol derivatives as new chemical
entities for cancer. J Mol Graph Model. 41:43–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
